Title
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial
Phase
Phase 4Study Type
InterventionalStatus
Terminated Results PostedIndication/Condition
Acute Pulmonary EdemaStudy Participants
111Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.
Dose use according to the product technical sheet
Dose use according to the product technical sheet
The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
Inclusion Criteria: Patients with acute pulmonary edema with dyspnoea and anxiety Exclusion Criteria: Patients with known severe liver disease. Patients with known severe renal disease. Patients with expectation of death from other illness during the course of the trial.
| Event Type | Organ System | Event Term | Midazolam | Morphine |
|---|
In hospital mortality
Length of hospital stay
